FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200248834> ?p ?o ?g. }

• W4200248834 endingPage "103" @default.
• W4200248834 startingPage "91" @default.
• W4200248834 abstract "Most patients with advanced-stage indolent non-Hodgkin lymphoma have multiple relapses. We assessed axicabtagene ciloleucel autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory indolent non-Hodgkin lymphoma.ZUMA-5 is a single-arm, multicentre, phase 2 trial being conducted at 15 medical cancer centres in the USA and two medical cancer centres in France. Patients were eligible if they were aged 18 years or older, with histologically confirmed indolent non-Hodgkin lymphoma (follicular lymphoma or marginal zone lymphoma), had relapsed or refractory disease, previously had two or more lines of therapy (including an anti-CD20 monoclonal antibody with an alkylating agent), and an Eastern Cooperative Oncology Group performance score of 0 or 1. Patients underwent leukapheresis and received conditioning chemotherapy (cyclophosphamide at 500 mg/m2 per day and fludarabine at 30 mg/m2 per day on days -5, -4, and -3) followed by a single infusion of axicabtagene ciloleucel (2 × 106 CAR T cells per kg) on day 0. The primary endpoint was overall response rate (complete response and partial response) assessed by an independent review committee per Lugano classification. The primary activity analysis was done after at least 80 treated patients with follicular lymphoma had been followed up for at least 12 months after the first response assessment at week 4 after infusion. The primary analyses were done in the per-protocol population (ie, eligible patients with follicular lymphoma who had 12 months of follow-up after the first response assessment and eligible patients with marginal zone lymphoma who had at least 4 weeks of follow-up after infusion of axicabtagene ciloleucel). Safety analyses were done in patients who received an infusion of axicabtagene ciloleucel. This study is registered with ClinicalTrials.gov, NCT03105336, and is closed to accrual.Between June 20, 2017, and July 16, 2020, 153 patients were enrolled and underwent leukapheresis, and axicabtagene ciloleucel was successfully manufactured for all enrolled patients. As of data cutoff (Sept 14, 2020), 148 patients had received an infusion of axicabtagene ciloleucel (124 [84%] who had follicular lymphoma and 24 [16%] who had marginal zone lymphoma). The median follow-up for the primary analysis was 17·5 months (IQR 14·1-22·6). Among patients who were eligible for the primary analysis (n=104, of whom 84 had follicular lymphoma and 20 had marginal zone lymphoma), 96 (92%; 95% CI 85-97) had an overall response and 77 (74%) had a complete response. The most common grade 3 or worse adverse events were cytopenias (104 [70%] of 148 patients) and infections (26 [18%]). Grade 3 or worse cytokine release syndrome occurred in ten (7%) patients and grade 3 or 4 neurological events occurred in 28 (19%) patients. Serious adverse events (any grade) occurred in 74 (50%) patients. Deaths due to adverse events occurred in four (3%) patients, one of which was deemed to be treatment-related (multisystem organ failure).Axicabtagene ciloleucel showed high rates of durable responses and had a manageable safety profile in patients with relapsed or refractory indolent non-Hodgkin lymphoma.Kite, a Gilead Company." @default.
• W4200248834 created "2021-12-31" @default.
• W4200248834 creator A5008419917 @default.
• W4200248834 creator A5016684714 @default.
• W4200248834 creator A5016764336 @default.
• W4200248834 creator A5021322016 @default.
• W4200248834 creator A5029619751 @default.
• W4200248834 creator A5034022345 @default.
• W4200248834 creator A5037526878 @default.
• W4200248834 creator A5040504519 @default.
• W4200248834 creator A5050341737 @default.
• W4200248834 creator A5050987906 @default.
• W4200248834 creator A5057643441 @default.
• W4200248834 creator A5060976304 @default.
• W4200248834 creator A5064150576 @default.
• W4200248834 creator A5064738578 @default.
• W4200248834 creator A5064752432 @default.
• W4200248834 creator A5066618983 @default.
• W4200248834 creator A5070180314 @default.
• W4200248834 creator A5072124588 @default.
• W4200248834 creator A5075930791 @default.
• W4200248834 creator A5081213752 @default.
• W4200248834 creator A5084789778 @default.
• W4200248834 creator A5085167557 @default.
• W4200248834 creator A5090442154 @default.
• W4200248834 date "2022-01-01" @default.
• W4200248834 modified "2023-10-18" @default.
• W4200248834 title "Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial" @default.
• W4200248834 cites W2082708772 @default.
• W4200248834 cites W2107925822 @default.
• W4200248834 cites W2119147717 @default.
• W4200248834 cites W2134861285 @default.
• W4200248834 cites W2160093471 @default.
• W4200248834 cites W2163790170 @default.
• W4200248834 cites W2310716991 @default.
• W4200248834 cites W2505010070 @default.
• W4200248834 cites W2566546873 @default.
• W4200248834 cites W2587684973 @default.
• W4200248834 cites W2735641564 @default.
• W4200248834 cites W2762226752 @default.
• W4200248834 cites W2769849420 @default.
• W4200248834 cites W2773804840 @default.
• W4200248834 cites W2775369717 @default.
• W4200248834 cites W2782959073 @default.
• W4200248834 cites W2903225254 @default.
• W4200248834 cites W2913987637 @default.
• W4200248834 cites W2952842269 @default.
• W4200248834 cites W3014583893 @default.
• W4200248834 cites W3024978145 @default.
• W4200248834 cites W3092484545 @default.
• W4200248834 doi "https://doi.org/10.1016/s1470-2045(21)00591-x" @default.
• W4200248834 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34895487" @default.
• W4200248834 hasPublicationYear "2022" @default.
• W4200248834 type Work @default.
• W4200248834 citedByCount "166" @default.
• W4200248834 countsByYear W42002488342021 @default.
• W4200248834 countsByYear W42002488342022 @default.
• W4200248834 countsByYear W42002488342023 @default.
• W4200248834 crossrefType "journal-article" @default.
• W4200248834 hasAuthorship W4200248834A5008419917 @default.
• W4200248834 hasAuthorship W4200248834A5016684714 @default.
• W4200248834 hasAuthorship W4200248834A5016764336 @default.
• W4200248834 hasAuthorship W4200248834A5021322016 @default.
• W4200248834 hasAuthorship W4200248834A5029619751 @default.
• W4200248834 hasAuthorship W4200248834A5034022345 @default.
• W4200248834 hasAuthorship W4200248834A5037526878 @default.
• W4200248834 hasAuthorship W4200248834A5040504519 @default.
• W4200248834 hasAuthorship W4200248834A5050341737 @default.
• W4200248834 hasAuthorship W4200248834A5050987906 @default.
• W4200248834 hasAuthorship W4200248834A5057643441 @default.
• W4200248834 hasAuthorship W4200248834A5060976304 @default.
• W4200248834 hasAuthorship W4200248834A5064150576 @default.
• W4200248834 hasAuthorship W4200248834A5064738578 @default.
• W4200248834 hasAuthorship W4200248834A5064752432 @default.
• W4200248834 hasAuthorship W4200248834A5066618983 @default.
• W4200248834 hasAuthorship W4200248834A5070180314 @default.
• W4200248834 hasAuthorship W4200248834A5072124588 @default.
• W4200248834 hasAuthorship W4200248834A5075930791 @default.
• W4200248834 hasAuthorship W4200248834A5081213752 @default.
• W4200248834 hasAuthorship W4200248834A5084789778 @default.
• W4200248834 hasAuthorship W4200248834A5085167557 @default.
• W4200248834 hasAuthorship W4200248834A5090442154 @default.
• W4200248834 hasConcept C126322002 @default.
• W4200248834 hasConcept C141071460 @default.
• W4200248834 hasConcept C143998085 @default.
• W4200248834 hasConcept C203092338 @default.
• W4200248834 hasConcept C2776694085 @default.
• W4200248834 hasConcept C2776755627 @default.
• W4200248834 hasConcept C2777058707 @default.
• W4200248834 hasConcept C2779263901 @default.
• W4200248834 hasConcept C2779338263 @default.
• W4200248834 hasConcept C2780653079 @default.
• W4200248834 hasConcept C2908647359 @default.
• W4200248834 hasConcept C535046627 @default.
• W4200248834 hasConcept C71924100 @default.
• W4200248834 hasConcept C90924648 @default.
• W4200248834 hasConcept C99454951 @default.
• W4200248834 hasConceptScore W4200248834C126322002 @default.

• next